|
CO-ADMINISTRATION MAY RESULT IN ALTERATION IN SERUM CONCENTRATIONS
|
CO-ADMINISTRATION MAY RESULT IN ALTERATION IN SERUM CONCENTRATIONS
|
CO-ADMINISTRATION MAY RESULT IN ALTERATION IN SERUM CONCENTRATIONS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
CO-ADMINISTRATION IN PATIENTS WITH RENAL IMPAIRMENT MAY RESULT IN INCREASED SERUM LEVELS OF CLARITHROMYCIN, SO ITS DOSES SHOULD BE REDUCED BY 50-75%
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS MAY RESULT IN INCREASED RISK OF MYOPATHY INCLUDING RHABDOMYOLYSIS
|
CO-ADMINISTRATION OF HMG-COA REDUCTASE INHIBITORS MAY RESULT IN INCREASED RISK OF MYOPATHY INCLUDING RHABDOMYOLYSIS
|
NEVIRAPINE BY INDUCING ACTIVITY OF CYP3A ENZYME DECREASES PLASMA CONCENTRATION OF THE DRUG
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
LOPINAVIR DECREASES ITS PLASMA CONCENTRATION
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
EFAVIRENZ DECREASE PLASMA CONCENTRATION OF THE DRUG
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS LIKE CARDIAC ARRHYTHMIAS
|
MAY LEAD TO LOSS OF VIROLOGIC RESPONSE & POSSIBLE RESISTANCE TO LOPINAVIR OR TO THE CLASS OF PROTEASE INHIBITORS OR OTHER CO-ADMINISTERED ANTIRETROVIRAL AGENTS
|
CO-ADMINISTRATION WITH ANTI-RETROVIRAL DRUGS MAY LEAD TO INCREASED CLEARANCE OF OTHER DRUG
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
CARBAMAZEPINE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
RITONAVIR INCREASES PLASMA CONCENTRATION OF THE DRUG & SO INCREASED CHANCES OF SIDE EFFECTS
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS SUCH AS PROLONGED OR INCREASED SEDATION OR RESPIRATORY DEPRESSION
|
CONTRAINDICATED DUE TO POTENTIAL FOR SERIOUS &/OR LIFE THREATENING REACTIONS SUCH AS PROLONGED OR INCREASED SEDATION OR RESPIRATORY DEPRESSION
|
DIDANOSINE IS GIVEN ON EMPTY STOMACH, ONE HR BEFORE OR TWO HRS AFTER THE OTHER MEDICINE
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|
LOPINAVIR INCREASES ITS PLASMA LEVELS
|